Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

NCT05660954 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.

NCT NCT05660954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05660954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Phase 2
Overall status
Completed
Start date
May 25, 2023
Completion date
November 30, 2025
Enrollment
41 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer